Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 9/20 | 0.67 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.52 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.52 |
| ▸ | MET | P08581 | 3/20 | 0.51 |
| ▸ | IKBKB | O14920 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1835257 | 1.00 | HRH3 (0.67) | HRH3ALKKCNH2METIKBKB | |
| SCHEMBL2349019 | 0.96 | HRH3 (0.69) | HRH3ALKMETIKBKB | |
| SCHEMBL2349018 | 0.96 | HRH3 (0.69) | HRH3ALKMETIKBKB | |
| Trifluoroacetic Acid SCHEMBL2344640 | 0.89 | HRH3 (0.62) | HRH3ALKKCNH2METIKBKB | |
| Trifluoroacetic Acid SCHEMBL2344639 | 0.89 | HRH3 (0.62) | HRH3ALKKCNH2METIKBKB | |
| SCHEMBL3276396 | 0.88 | HRH3 (0.57) | HRH3MET | |
| SCHEMBL3276400 | 0.88 | HRH3 (0.57) | HRH3MET | |
| SCHEMBL1794728 | 0.87 | HRH3 (0.61) | HRH3KCNH2METIKBKB | |
| SCHEMBL1794727 | 0.87 | HRH3 (0.61) | HRH3KCNH2METIKBKB | |
| Hydrochloric Acid SCHEMBL5499999 | 0.87 | HRH3 (0.56) | HRH3MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1868991-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2014-07-30 | — | — | EP | claimed |
| US-8178528-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2012-05-15 | — | — | US | claimed |
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | claimed |
| EP-1868991-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-12-26 | — | — | EP | claimed |
| WO-2006107661-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | claimed |
| EP-1868991-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2014-07-30 | — | — | EP | disclosed |
| EP-1868991-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2014-07-30 | — | — | EP | disclosed |
| US-8178528-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178528-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| US-8178528-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2012-05-15 | — | — | US | disclosed |
| EP-1904442-B1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | LILLY CO ELI (US) | 2011-09-07 | — | — | EP | disclosed |
| US-8008296-B2 | Histamine H3 receptor agents, preparation and therapeutic uses | ELI LILLY AND COMPANY (US) | 2011-08-30 | — | — | US | disclosed |
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY | 2010-06-24 | — | — | US | disclosed |
| EP-1904442-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2008-04-02 | — | — | EP | disclosed |
| EP-1868991-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-12-26 | — | — | EP | disclosed |
| US-7195751-B2 | Compositions and kits pertaining to analyte determination | APPLERA CORPORATION (US) | 2007-03-27 | — | — | US | disclosed |
| WO-2007005503-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2007-01-11 | — | — | WO | disclosed |
| WO-2006107661-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | ELI LILLY AND COMPANY (US) | 2006-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160406-A1 | HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES | HRH3, HRH4, HCRTR1 | HRH3 1/4885ALK 1021/4885KCNH2 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.